Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians

  • KW Miskowiak
    Copenhagen Affective Disorder Research Centre (CADIC) Psychiatric Centre Copenhagen Copenhagen University Hospital Rigshospitalet, Copenhagen Denmark
  • KE Burdick
    Department of Psychiatry Brigham and Women's Hospital Harvard Medical School Boston MA USA
  • A Martinez‐Aran
    Clinical Institute of Neuroscience Hospital Clinic University of Barcelona IDIBAPS CIBERSAM Barcelona Catalonia Spain
  • CM Bonnin
    Clinical Institute of Neuroscience Hospital Clinic University of Barcelona IDIBAPS CIBERSAM Barcelona Catalonia Spain
  • CR Bowie
    Department of Psychology Queen's University Kingston Canada
  • AF Carvalho
    Department of Clinical Medicine and Translational Psychiatry Research Group Faculty of Medicine Federal University of Ceará Fortaleza Brazil
  • P Gallagher
    Institute of Neuroscience Newcastle University Newcastle‐upon‐Tyne UK
  • B Lafer
    Bipolar Disorder Research Program Departamento de Psiquiatria Faculdade de Medicina FMUSP Universidade de Sao Paulo Sao Paulo SP Brazil
  • C López‐Jaramillo
    Research Group in Psychiatry Department of Psychiatry Universidad de Antioquia Medellín Colombia
  • T Sumiyoshi
    Department of Clinical Epidemiology Translational Medical Center National Center of Neurology and Psychiatry Tokyo Japan
  • RS McIntyre
    Mood Disorders Psychopharmacology Unit Brain and Cognition Discovery Foundation University of Toronto Toronto Canada
  • A Schaffer
    Department of Psychiatry University of Toronto Toronto Canada
  • RJ Porter
    Department of Psychological Medicine University of Otago Christchurch New Zealand
  • S Purdon
    Department of Psychiatry University of Alberta Edmonton Canada
  • IJ Torres
    Department of Psychiatry University of British Columbia Vancouver Canada
  • LN Yatham
    Department of Psychiatry University of British Columbia Vancouver Canada
  • AH Young
    Department of Psychological Medicine Institute of Psychiatry, Psychology and Neuroscience King's College London London UK
  • LV Kessing
    Copenhagen Affective Disorder Research Centre (CADIC) Psychiatric Centre Copenhagen Copenhagen University Hospital Rigshospitalet, Copenhagen Denmark
  • E Vieta
    Clinical Institute of Neuroscience Hospital Clinic University of Barcelona IDIBAPS CIBERSAM Barcelona Catalonia Spain

この論文をさがす

説明

<jats:sec><jats:title>Objectives</jats:title><jats:p>Cognition is a new treatment target to aid functional recovery and enhance quality of life for patients with bipolar disorder. The International Society for Bipolar Disorders (ISBD) Targeting Cognition Task Force aimed to develop consensus‐based clinical recommendations on whether, when and how to assess and address cognitive impairment.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The task force, consisting of 19 international experts from nine countries, discussed the challenges and recommendations in a face‐to‐face meeting, telephone conference call and email exchanges. Consensus‐based recommendations were achieved through these exchanges with no need for formal consensus methods.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The identified questions were: (I) Should cognitive screening assessments be routinely conducted in clinical settings? (II) What are the most feasible screening tools? (III) What are the implications if cognitive impairment is detected? (IV) What are the treatment perspectives? Key recommendations are that clinicians: (I) formally screen cognition in partially or fully remitted patients whenever possible, (II) use brief, easy‐to‐administer tools such as the Screen for Cognitive Impairment in Psychiatry and Cognitive Complaints in Bipolar Disorder Rating Assessment, and (III) evaluate the impact of medication and comorbidity, refer patients for comprehensive neuropsychological evaluation when clinically indicated, and encourage patients to build cognitive reserve. Regarding question (IV), there is limited evidence for current evidence‐based treatments but intense research efforts are underway to identify new pharmacological and/or psychological cognition treatments.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This task force paper provides the first consensus‐based recommendations for clinicians on whether, when, and how to assess and address cognition, which may aid patients’ functional recovery and improve their quality of life.</jats:p></jats:sec>

収録刊行物

被引用文献 (6)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ